Press Release
June 2, 2021

Goodwin Enhances Antitrust Capabilities Amid Increasing M&A Activity with Partner Arman Oruc in Los Angeles

Global law firm Goodwin announced today that Arman Oruc has joined the firm as partner in the Antitrust and Competition practice, resident in the Los Angeles office. His appointment follows the recent arrival of antitrust partner Andy Lacy in April.

“Competition authorities have increased their focus on the life sciences, technology, and private equity industries, in which our clients are incredibly active,” said Joanne Gray, chair of Goodwin’s Litigation department. “Arman’s knowledge and experience in both merger clearance and antitrust litigation in these industries, combined with his deep life sciences experience, gives him a unique perspective that will be an immediate benefit to our clients. We are thrilled to welcome him to the Goodwin partnership.”

Oruc has extensive experience advising on antitrust issues, including regulatory clearance of mergers and acquisitions across multiple jurisdictions, formulation of intellectual property strategies, standard-setting collaborations, and pricing and product design issues. He has acted as lead counsel in complex civil antitrust litigations, and has defended clients against criminal and civil investigations by the DOJ, FTC, European Commission and state regulators. After practicing for seventeen years as an antitrust lawyer and launching his prior law firm’s Washington, D.C. office, Oruc was part of the founding team of Biosplice Therapeutics in 2013, where he also served as Chief Legal Officer and a member of the Board.

“I am excited to return to private practice as a partner at Goodwin, a firm recognized for being a leader in serving innovators and investors in complex transactions, including in the life sciences industry,” said Oruc. “I look forward to working with Goodwin’s global antitrust and M&A team to help clients navigate competition-related issues.”

Over the past year, Goodwin has ranked at the top of the global M&A league tables. Refinitiv named Goodwin the number one legal advisor (by deal count) for global M&A in 2020, and Mergermarket’s Deal Drivers FY20 reports named Goodwin the number one firm (by deal count) for Pharma, Medical, and Biotech M&A in North America. This success has continued in 2021, as Refinitiv’s Q1 global M&A league tables named Goodwin the number one legal advisor (by deal count) for global M&A as well as mid-market and small-cap global M&A.

Goodwin’s Antitrust and Competition lawyers have advised clients — from the largest Fortune 500 companies to emerging growth companies — on more than 2,500 transactions before US and international antitrust agencies. The team has successfully defended hundreds of matters through the Second Request process and other intensive government investigations.